Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Prospects for HIV control in South Africa: a model-based analysis.

Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, Boulle A, Meyer-Rath G.

Glob Health Action. 2016 Jun 8;9:30314. doi: 10.3402/gha.v9.30314. eCollection 2016.

2.

The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.

Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, Churchyard G, Watts C, Vickerman P.

PLoS Med. 2015 Sep 1;12(9):e1001869. doi: 10.1371/journal.pmed.1001869. eCollection 2015 Sep.

3.

Attrition through multiple stages of pre-treatment and ART HIV care in South Africa.

Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sanne I.

PLoS One. 2014 Oct 20;9(10):e110252. doi: 10.1371/journal.pone.0110252. eCollection 2014.

4.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

5.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2013 Dec 10;2(1):23-34.

6.

Resource Utilization and Costs of Care prior to ART Initiation for Pediatric Patients in Zambia.

Iyer HS, Scott CA, Lembela Bwalya D, Meyer-Rath G, Moyo C, Bolton Moore C, Larson BA, Rosen S.

AIDS Res Treat. 2014;2014:235483. doi: 10.1155/2014/235483. Epub 2014 Mar 10.

7.

Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.

Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, Delany-Moretlwe S, Mertenskoetter T, Rees H, Vickerman P, Watts CH.

BMC Infect Dis. 2014 Jan 9;14:14. doi: 10.1186/1471-2334-14-14.

8.

Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa.

Schnippel K, Long L, Meyer-Rath G, Sanne I, Rosen S, Stevens W.

S Afr Med J. 2013 Jul;103(7):436. No abstract available.

PMID:
23946950
9.

Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis.

Scott CA, Iyer H, Bwalya DL, McCoy K, Meyer-Rath G, Moyo C, Bolton-Moore C, Larson B, Rosen S.

PLoS One. 2013 Jun 28;8(6):e67910. doi: 10.1371/journal.pone.0067910. Print 2013.

10.

Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa.

Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, Rosen S.

S Afr Med J. 2013 Jan 14;103(2):101-6. doi: 10.7196/samj.6182.

PMID:
23374320
11.

Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa.

Meyer-Rath G, Brennan AT, Fox MP, Modisenyane T, Tshabangu N, Mohapi L, Rosen S, Martinson N.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):322-328.

12.

Cost and outcomes of paediatric antiretroviral treatment in South Africa.

Meyer-Rath G, Brennan A, Long L, Ndibongo B, Technau K, Moultrie H, Fairlie L, Coovadia A, Rosen S.

AIDS. 2013 Jan 14;27(2):243-50. doi: 10.1097/QAD.0b013e32835a5b92.

PMID:
23014517
13.

Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa.

Meyer-Rath G, Miners A, Santos AC, Variava E, Venter WD.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e25-32. doi: 10.1097/QAI.0b013e31826cc575.

PMID:
22895437
14.

Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study.

Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, Govindasamy D, van Schaik N, Wood R, Bekker LG.

PLoS Med. 2012;9(8):e1001281. doi: 10.1371/journal.pmed.1001281. Epub 2012 Aug 7.

15.

HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.

HIV Modelling Consortium Treatment as Prevention Editorial Writing Group.

PLoS Med. 2012;9(7):e1001259. doi: 10.1371/journal.pmed.1001259. Epub 2012 Jul 10. Review.

16.

HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Meyer-Rath G, Over M.

PLoS Med. 2012;9(7):e1001247. doi: 10.1371/journal.pmed.1001247. Epub 2012 Jul 10.

17.

The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.

Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S.

PLoS One. 2012;7(5):e36966. doi: 10.1371/journal.pone.0036966. Epub 2012 May 31.

18.

Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.

Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens WS, Rosen S.

Trop Med Int Health. 2012 Sep;17(9):1142-51. doi: 10.1111/j.1365-3156.2012.03028.x. Epub 2012 Jun 12.

19.

The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.

Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G.

Sex Transm Dis. 2011 May;38(5):401-9. doi: 10.1097/OLQ.0b013e31820b8bc8.

PMID:
21317689
20.

The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi.

Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G.

AIDS Care. 2009 Nov;21(11):1388-94. doi: 10.1080/09540120902884042.

PMID:
20024715
Items per page

Supplemental Content

Loading ...
Write to the Help Desk